GelStat Corp.

Study shows positive results for liquid gel migraine therapy

Published in Drug Law Weekly, March 16th, 2004

GelStat Corp. (GSAC) announced preliminary results from an open-label study in which GelStat Migraine was effective in eliminating migraine pain or preventing its progression in 83% of patients treating early in the course of an attack.

The data was presented at the 17th annual Practicing Physician's Approach to the Difficult Headache Patient.

GelStat Migraine is a patent pending OTC (over-the-counter) medication for acute relief from pain and associated symptoms of migraine and migraine-like headaches. It is a liquid gel provided in single dose dispensers for sublingual (under the tongue) administration. The company's drug delivery technology, known...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2004-03-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry